Companion diagnostics regulatory affairs sit at the centre of precision medicine, where in vitro diagnostics are used to guide treatment decisions linked to a specific medicinal product. At BaxMed, we see companion diagnostics CDx as a regulated bridge between drug development and patient care, with regulatory requirements that demand early planning, technical depth, and close alignment across development teams.

In precision medicine, a companion diagnostic identifies patients who are likely to benefit from a treatment or who may be at increased risk of adverse reactions. That role places the test directly in the regulatory scope of clinical decision making. Our work in companion diagnostics regulatory affairs focuses on building a regulatory strategy that supports safe and effective use while enabling market access across relevant regulatory pathways.

Regulatory expectations for companion diagnostics

Companion diagnostics are classed as in vitro diagnostics, yet they carry additional obligations because of their link to a medicinal product. Regulatory bodies expect evidence that the test reliably identifies patients and supports treatment decisions based on sound scientific validity and clinical performance. At BaxMed, we approach this by aligning regulatory strategy with the intended use, target population, and therapeutic context from the outset.

Regulatory pathways vary by region, yet common themes apply. Technical documentation must demonstrate analytical performance, clinical performance, and the relationship between the diagnostic and the drug. Study designs need to show that the test result has a clear role in selecting or excluding patients for treatment. We support this alignment so that regulatory affairs activity does not become disconnected from drug development timelines.

Regulatory strategy and development planning

A companion diagnostics regulatory strategy works best when it is established early. BaxMed helps organisations define regulatory requirements alongside development milestones, rather than treating submissions as a late stage activity. This includes planning interactions with regulatory bodies, selecting appropriate study designs, and confirming how data will be used across submissions for both the diagnostic and the medicinal product.

In many cases, companion diagnostic regulatory consultants are brought in to help manage complexity across multiple regulatory frameworks. Our role is to provide structure and clarity, focusing on how technical documentation, clinical evidence, and quality systems come together to support approval. This approach reduces rework and supports consistent messaging across regulatory submissions.

Quality systems and technical documentation

A compliant quality management system underpins all companion diagnostics regulatory affairs activity. We support the implementation and maintenance of systems that meet applicable regulatory requirements for in vitro diagnostics, with controls that support design, development, and post market obligations. Quality processes must link directly to technical documentation, ensuring traceability from intended use through to clinical performance evidence.

Technical documentation for companion diagnostics cdx is more than a regulatory formality. It is the structured record that demonstrates scientific validity, performance, and risk control. We focus on building documentation that reflects the reality of development and study execution, supporting review by a notified body or other regulatory bodies without unnecessary complexity.

Clinical performance and patient identification

Clinical performance evidence is central to companion diagnostics regulatory affairs. Regulators expect clear data showing how the test identifies patients and supports treatment decisions. BaxMed work with development teams to ensure study designs are appropriate for the diagnostic claim and aligned with the therapeutic indication. This includes consideration of sample selection, endpoints, and data integration with drug development studies.

By keeping regulatory strategy connected to clinical planning, we support submissions that clearly demonstrate safe and effective use. This helps reduce uncertainty during review and supports smoother progress through regulatory pathways.

Market access and ongoing compliance in companion diagnostics (CDx) regulatory affairs

Market access for companion diagnostics depends on successful regulatory approval and sustained compliance. We support organisations beyond initial submissions, helping maintain alignment with evolving regulatory requirements and post market expectations. Companion diagnostics regulatory affairs do not end at approval, they continue through lifecycle management, changes, and performance monitoring.

Our approach to companion diagnostics regulatory affairs is grounded in practical experience with in vitro diagnostics and precision medicine. By integrating regulatory strategy, quality management systems, and technical documentation, we help organisations navigate regulatory requirements with confidence while supporting timely access to patients who rely on these tests.